Live
FierceBiotechAptose, facing cash crunch, exits blood cancer pact after Hanmi buyout blocks developmentFierceBiotechRegenxbio reaps pivotal win for Duchenne muscular dystrophy gene therapyCellTransplantation of encapsulated mitochondria alleviates dysfunction in mitochondrial and Parkinson’s disease modelsEndpoints NewsRegenxbio hits Duchenne gene therapy milestone, eyes 2027 FDA approvalEndpoints NewsBeOne’s next-gen BCL2 inhibitor wins FDA approval, taking aim at VenclextaThermo FisherBetween Mettler-Toledo International and Thermo Fisher Scientific, Which Stock Looks Set to Break Out? - TrefisAgilentAgilent Technologies (A) Valuation Check As New Biopharma Collaborations And Logic Analyzers Expand Growth Story - simplywall.stPfizerShould you buy pharma stocks? Dr Reddy's, Pfizer - Target prices after Q4 results - Business TodayeLifeEffort produces after-effects costly for others but valued for selfeLifeA meta-analysis suggests that TMS targeting the hippocampal network selectively improves episodic memoryInsilico MedicineSuzhou Ribo Life Science And Insilico Medicine Forge Strategic Alliance To Accelerate AI Powered siRNA Drug Development - BioPharma APACClinical OMICsASGCT 2026: Timothy Yu Wins Jerry Mendell Award For N-of-1 Therapies
Endpoints News Mar 29, 2026

Kailera plans IPO for Phase 3 obesity drug from Hengrui

Kailera plans IPO for Phase 3 obesity drug from Hengrui

Original
Body unavailable. Use the original source.